MedTrace Logo

Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

NCT05418660 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-09-18

No results posted yet for this study

Summary

Retrospective/ prospective, multicentre, international observational study on long-responders with non-small cell lung carcinoma patients treated with anti Programmed cell Death 1/ Programmed cell Death Ligand 1 (anti-PD1/PD-L1) in any line of treatment for at least 24 months with response partial/complete response or disease stability. Patients will be divided into two cohorts based on whether they stopped treatment at 24 months (not for toxicity) or continued by clinical choice and stratified according to treatment line and baseline PD-L1 expression.

Conditions

Interventions

DRUG

Immunotherapy

At least 24 months with Pembrolizumab, Nivolumab or Atezolizumab in any treatment line

Sponsors & Collaborators

  • Azienda Ospedaliera San Gerardo di Monza

    collaborator OTHER

  • University of Milano Bicocca

    lead OTHER

Principal Investigators

  • Diego Cortinovis, MD · Fondazione IRCCS San Gerardo dei Tintori, Monza

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05418660 on ClinicalTrials.gov